The brain disease artificial intelligence (AI) corporation Neurophet announced on the 26th that it has appointed Atsushi Iwata, deputy director of the Tokyo Metropolitan Institute of Gerontology (Ph.D.), as a scientific advisor. He is a specialist in neurology and leads clinical research on neuroimaging for Alzheimer's disease in Japan.
Dr. Iwata also concurrently serves as the outpatient department director at Tokyo Medical University Hospital and provides consulting services to the Japanese pharmaceutical company Eisai. He is among the medical professionals actively prescribing the anti-amyloid treatment Leqembi (ingredient name lecanemab) in Japan.
Dr. Iwata provides consulting on research and development related to neuroimaging for Alzheimer's disease at Neurophet. He plans to assist in entering the Japanese market and to create collaborative opportunities with global corporations. Bin Jun-gil, co-CEO of Neurophet, noted, "We will create synergies in our research and development and commercialization strategies."